6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the treatment of cancer patients, cisplatin (CDDP) exhibits serious cardiac and renal toxicities, while classical combinations related to CDDP are unable to solve these problems and may result in worse prognosis. Alternately, this study covalently conjugated 6-mercaptopurine (6MP) onto the surface of mercapto-modified mesoporous silica nanoparticles (MSNS) to form MSNS-6MP and loaded CDDP into the holes on the surface of MSNS-6MP to form MSNS-6MP/CDDP, a tumor-targeting nano-releasing regime for CDDP and 6MP specifically. In the S180 mouse model, the anti-tumor activity and overall survival of MSNS-6MP/CDDP (50 mg·kg −1·day −1, corresponding to 1 mg·kg −1·day −1 of 6MP and 5 mg·kg −1·day −1 of CDDP) were significantly higher than those of CDDP alone (5 mg·kg −1·day −1) or CDDP (5 mg·kg −1·day −1) plus 6MP (1 mg·kg −1·day −1). The assays of serum alanine aminotransferase, aspartate aminotransferase and creatinine, as well as the images of myocardium and kidney histology, support that MSNS-6MP/CDDP is able to completely eliminate liver, kidney and heart toxicities induced by CDDP alone or CDDP plus 6MP.

          Related collections

          Most cited references 30

          • Record: found
          • Abstract: found
          • Article: not found

          Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine.

          Medicine can benefit significantly from advances in nanotechnology because nanoscale assemblies promise to improve on previously established therapeutic and diagnostic regimes. Over the past decade, the use of delivery platforms has attracted attention as researchers shift their focus toward new ways to deliver therapeutic and/or diagnostic agents and away from the development of new drug candidates. Metaphorically, the use of delivery platforms in medicine can be viewed as the "bow-and-arrow" approach, where the drugs are the arrows and the delivery vehicles are the bows. Even if one possesses the best arrows that money can buy, they will not be useful if one does not have the appropriate bow to deliver the arrows to their intended location. Currently, many strategies exist for the delivery of bioactive agents within living tissue. Polymers, dendrimers, micelles, vesicles, and nanoparticles have all been investigated for their use as possible delivery vehicles. With the growth of nanomedicine, one can envisage the possibility of fabricating a theranostic vector that could release powerful therapeutics and diagnostic markers simultaneously and selectively to diseased tissue. In our design of more robust theranostic delivery systems, we have focused our attention on using mesoporous silica nanoparticles (SNPs). The payload "cargo" molecules can be stored within this robust domain, which is stable to a wide range of chemical conditions. This stability allows SNPs to be functionalized with stimulus-responsive mechanically interlocked molecules (MIMs) in the shape of bistable rotaxanes and psuedorotaxanes to yield mechanized silica nanoparticles (MSNPs). In this Account, we chronicle the evolution of various MSNPs, which came about as a result of our decade-long collaboration, and discuss advances in the synthesis of novel hybrid SNPs and the various MIMs which have been attached to their surfaces. These MIMs can be designed in such a way that they either change shape or shed off some of their parts in response to a specific stimulus, such as changes in redox potential, alterations in pH, irradiation with light, or the application of an oscillating magnetic field, allowing a theranostic payload to be released from the nanopores to a precise location at the appropiate time. We have also shown that these integrated systems can operate not only within cells, but also in live animals in response to pre-existing biological triggers. Recognizing that the theranostics of the future could offer a fresh approach to the treatment of degenerative diseases including cancer, we aim to start moving out of the chemical domain and into the biological one. Some MSNPs are already being tested in biological systems.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Direct synthesis of ordered mesoporous carbons.

            Ordered mesoporous carbon materials have recently aroused great research interest because of their widespread applications in many areas such as adsorbents, catalysts and supports, gas storage hosts, and electrode materials. The direct synthesis strategy from organic-organic self-assembly involving the combination of polymerizable precursors and block copolymer templates is expected to be more flexible in preparing mesoporous carbons, compared with the traditional nanocasting strategy of complicated and high-cost procedures using mesoporous silica materials as the hard template. In this review, we present the fundamentals and recent advances related to the field of ordered mesoporous carbon materials from the direct synthesis strategy of block copolymer soft-templating, with a focus on their controllable preparation, modification and potential applications. Under the guidance of their formation mechanism, the preparation of ordered mesoporous carbons are discussed in detail by consulting different experimental conditions, including synthetic pathways, precursors, catalysts and templates. Both the mesopore size and morphology control are introduced. The potential applications of pure mesoporous carbons, nonmetallic- and metallic-modified mesoporous carbons, and some interpenetrating carbon-based composites are demonstrated. Furthermore, remarks on the challenges and perspectives of research directions are proposed for further development of the ordered mesoporous carbons (232 references).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.

              The platinum analogues, cisplatin and carboplatin, are among the most widely used chemotherapeutic agents in oncology. Both agents have a broad spectrum of clinical activity in numerous malignancies including gynaecological cancers, germ cell tumours, head and neck cancer, thoracic cancers and bladder cancer. Although the final mechanism of inducing tumour cell apoptosis is similar for both compounds, cisplatin has been shown to be more effective in treating specific tumour types. Whilst more favourable toxicity profiles are often associated with carboplatin, this can frequently translate to inferior response in certain malignancies. This review succinctly collates the evidence for the preferential use of these platinum analogues in particular settings in addition to the long-standing dilemma surrounding the paucity of biomarkers predicting response to these agents.
                Bookmark

                Author and article information

                Journal
                Drug Des Devel Ther
                Drug Des Devel Ther
                Drug Design, Development and Therapy
                Drug Design, Development and Therapy
                Dove Medical Press
                1177-8881
                2016
                01 December 2016
                : 10
                : 3933-3946
                Affiliations
                [1 ]Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, College of Pharmaceutical Sciences, Capital Medical University, Beijing, People’s Republic of China
                [2 ]Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan
                Author notes
                Correspondence: Ming Zhao; Shiqi Peng, Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, College of Pharmaceutical Sciences, Capital Medical University, No. 10, Xitoutiao, You An Men, Beijing, 100069, People’s Republic of China, Tel +86 10 8391 1528, Fax +86 10 8391 1533, Email sqpeng@ 123456bjmu.edu.cn ; mingzhao@ 123456bjmu.edu.cn
                Article
                dddt-10-3933
                10.2147/DDDT.S116286
                5138022
                27942204
                © 2016 Lv et al. This work is published and licensed by Dove Medical Press Limited

                The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

                Categories
                Original Research

                Comments

                Comment on this article